Comparative Pharmacology
Head-to-head clinical analysis: MYOZYME versus STRENSIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOZYME versus STRENSIQ.
MYOZYME vs STRENSIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA) that hydrolyzes glycogen to glucose in lysosomes. It replaces deficient GAA enzyme activity in patients with Pompe disease.
Human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) that hydrolyzes inorganic pyrophosphate (PPi), a natural inhibitor of hydroxyapatite crystal growth, thereby promoting bone mineralization.
20 mg/kg IV every 2 weeks.
6 mg/kg administered subcutaneously once weekly.
None Documented
None Documented
The terminal elimination half-life of alglucosidase alfa is approximately 2.3 hours at steady state. This short half-life necessitates weekly intravenous infusions to maintain therapeutic enzyme levels in target tissues.
Terminal elimination half-life approximately 5.1 days (123 hours) in adults; supports once-weekly subcutaneous dosing for sustained pharmacodynamic effect.
Renal elimination is the primary route of clearance for alglucosidase alfa. Following intravenous administration, the drug is cleared via catabolism into small peptides and amino acids, which are then excreted renally. Less than 5% of the administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Renal (primarily via proteolytic catabolism into small peptides and amino acids); negligible biliary or fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy